<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1314">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01683500</url>
  </required_header>
  <id_info>
    <org_study_id>CCESWT01</org_study_id>
    <nct_id>NCT01683500</nct_id>
  </id_info>
  <brief_title>Calcinosis Cutis: Therapeutic Effects of Extracorporeal Shock Wave Therapy (ESWT)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <authority>Switzerland: Swissmedic</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with calcinosis cutis due to connective tissue disease get a shock wave therapy.
      The shock wave therapy will be done in 3 sessions with one week interval. The outcome
      parameters are: change in pain, size of the calcinosis, of possible ulcers and intake of
      painkillers.

        -  Trial with medical device
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>change in pain</measure>
    <time_frame>after 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Calcinosis Cutis Due to Connective Tissue Disease</condition>
  <arm_group>
    <arm_group_label>shock wave therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>shock wave therapy with Modulith SLK (Storz)</intervention_name>
    <description>Three sessions with shock wave therapy, interval of one week.</description>
    <arm_group_label>shock wave therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Age of 18

          -  Calcinosis cutis due to connective tissue disease

          -  information about ESWT given

          -  Patient understands the study and signs the informed consent

        Exclusion criteria:

          -  No ESWT done

          -  cuagulopathy

          -  sepsis

          -  pregnancy

          -  pace maker

          -  severe disease in the opinion of the investigator

          -  cardiac risk with NYHA III-IV

          -  Ehlers-Danlos-Syndrome
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra Blumhardt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Division of Rheumatology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra Blumhardt, MD</last_name>
    <phone>+41 (0)44 255 11 11</phone>
    <email>sandra.blumhardt@usz.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Zurich, Division of Rheumatology</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 12, 2012</lastchanged_date>
  <firstreceived_date>September 7, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcinosis</mesh_term>
    <mesh_term>Connective Tissue Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
